Kirby McInerney LLP Investigates BioAge Labs, Inc. on Behalf of Investors

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is currently conducting an investigation into potential claims against BioAge Labs, Inc. ("BioAge" or the "Company") regarding the matter of BIOA. This investigation seeks to determine whether BioAge or its officers have breached federal securities laws or engaged in other illegal business activities.

On December 6, 2024, BioAge revealed the discontinuation of its STRIDES Phase 2 trial concerning its main product candidate, azelaprag. The company cited safety issues as the reason for this decision, specifically indicating that liver transaminitis was identified in participants receiving azelaprag. BioAge stated that the choice to halt the STRIDES Phase 2 study was clear due to the developing safety profile associated with the doses being tested.

Following this announcement, BioAge's stock experienced a significant decline, plummeting by $15.44 per share, which represents an approximate 76% drop. The stock fell from a price of $20.09 per share on December 6, 2024, to a closing price of $4.65 by December 9, 2024.

Investors who have purchased or acquired BioAge securities, or those who have relevant information regarding the situation, are encouraged to reach out to Thomas W. Elrod of Kirby McInerney LLP via email at [email protected]. Alternatively, interested parties can complete the contact form provided below to discuss their rights and interests in relation to these matters, free of charge.

Kirby McInerney LLP is a plaintiffs' law firm headquartered in New York that specializes in securities, antitrust, whistleblower, and consumer litigation. The firm has secured substantial recoveries totaling billions of dollars for shareholders through its efforts in securities litigation.

This announcement may be regarded as Attorney Advertising in certain regions, based on applicable legal standards and ethical guidelines.

investigation, securities, lawsuit